Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  CVS Health Corporation    CVS

My previous session
Most popular
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweetsMarketScreener Strategies
The feature you requested does not exist. However, we suggest the following feature:

CVS Health : Applauds FDA's Announcement to Restrict Flavored Tobacco Products

share with twitter share with LinkedIn share with facebook
share via e-mail
11/15/2018 | 05:24pm CET

WOONSOCKET, R.I., Nov. 15, 2018/PRNewswire/ -- CVS Health (NYSE: CVS), the nation's first and only national pharmacy chain to have eliminated the sale of tobacco products from its retail stores, today announced its support for the U.S. Food and Drug Administration's plans to restrict access to flavored tobacco and e-cigarette products in the retail setting and impose stricter age-verification requirements for online sales. In addition to eliminating the sale of tobacco products in 2014, CVS Health has never sold e-cigarettes or vaping devices in any of its CVS Pharmacy locations.

'We applaud the FDA's decision to restrict access to flavored tobacco and e-cigarette products, which have been expertly marketed and targeted at teens and young adults and has contributed to a dramatic rise in e-cigarette use among high school students,' said Troyen Brennan, M.D., M.P.H. and Chief Medical Officer for CVS Health. 'E-cigarette use among teens has also been directly correlated to a spike in cigarette smoking, after reaching historic lows. Through these new regulations, the FDA can help curb the e-cigarette epidemic and make a positive impact on public health for generations to come.'

CVS Health has a long history of helping people lead tobacco-free lives, with a recent focus on educating young people on the dangers of smoking and the use of e-cigarettes. Recognizing the impact the company could have on reducing smoking and tobacco use following its tobacco exit in 2014, CVS Health launched Be The First, a five-year $50 millioninitiative to help deliver the nation's first tobacco-free generation.

Through partnerships with Campaign for Tobacco-Free Kids, CATCH Global Foundation, Stanford Medicine, and Truth Initiative, CVS Health and the CVS Health Foundation are currently funding and supporting several programs that educate students on e-cigarettes and help them build knowledge and skills to resist peer pressure and marketing influences to try e-cigarettes. Most recently, the company launched a campaign with DoSomething.org to empower young people to speak up against e-cigarette flavoring and marketing towards youth.

Since it was first introduced in 2016, Be The First has delivered meaningful support to the country's ongoing efforts to prevent smoking and nicotine addiction among youth which is critical to ending tobacco use in the United States.

By funding programs with the nation's leading tobacco control advocates, including the American Cancer Society, American Lung Association and Truth Initiative, CVS Health and its Foundation has helped reach more than 5 million young people with effective anti-smoking education and healthy behavior programming and is helping 146 colleges and universities advocate for, adopt and implement tobacco-free campus policies.

About CVS Health

CVS Health is a pharmacy innovation company helping people on their path to better health. Through its more than 9,800 retail locations, approximately 1,100 walk-in medical clinics, a leading pharmacy benefits manager with approximately 93 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty pharmacy services, and a leading stand-alone Medicare Part D prescription drug plan, the Company enables people, businesses and communities to manage health in more affordable and effective ways. This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at https://www.cvshealth.com.

Media Contacts:
Joe Goode, 401-770-9820

Mary Gattuso, 401-770-9811
Mary. Gattuso@CVSHealth.com



CVS Health Corporation published this content on 15 November 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 15 November 2018 16:23:09 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
11/15CVS HEALTH : Applauds FDA's Announcement to Restrict Flavored Tobacco Products
11/15CVS HEALTH : Teams Up with Philadelphia Job Corps, Philadelphia Works and Philad..
11/14CVS HEALTH : Coram CVS Specialty Home Infusion Services Awarded Home Care Accred..
11/14CVS HEALTH : Coram CVS Specialty® Home Infusion Services Awarded Home Care Accre..
11/07MINUTECLINIC : Opens First Walk-in Medical Clinic in San Francisco
11/06CVS HEALTH : and Booking Holdings climb while Ralph Lauren sinks
11/06CVS HEALTH : Lays Out Vision for Future as Aetna Merger Looms -- Update
11/06CVS HEALTH : Lays Out Vision for Future as Aetna Merger Looms -- Update
11/06CVS HEALTH : Ahead of elections, industrials lead US stocks higher
11/06CVS Up Over 4%, on Pace for Best Year Since 2014 -- Data Talk
More news
News from SeekingAlpha
11/15California insurance regulator signs off on CVS/Aetna tie-up 
11/15Top Merger Stocks Held By Fund Managers, Mid-Q4 2018 
11/14THE 'OTHER' A+ COMPANIES : A Golden Ticket? Part 1 
11/13ClearBridge Appreciation Strategy Portfolio Manager Commentary Q3 2018 
11/12Vulcan Value Partners Quarterly Letter Q3 2018 
Financials ($)
Sales 2018 189 B
EBIT 2018 9 995 M
Net income 2018 1 470 M
Debt 2018 19 278 M
Yield 2018 2,49%
P/E ratio 2018 51,91
P/E ratio 2019 11,99
EV / Sales 2018 0,53x
EV / Sales 2019 0,50x
Capitalization 80 821 M
Duration : Period :
CVS Health Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CVS HEALTH CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 92,6 $
Spread / Average Target 17%
EPS Revisions
Larry J. Merlo President, CEO & Non-Independent Director
David Wyatt Dorman Chairman
Jonathan C. Roberts Chief Operating Officer & Executive Vice President
Eva C. Boratto Chief Financial Officer & Executive Vice President
Troyen A. Brennan Chief Medical Officer & Executive Vice President
Sector and Competitors